Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Okay. Southeast. Mr. Nelson, can you tell by? René indicated that an English tea. The party conference in Qatar hosted a webcast featuring the Orion Corporation. Lisa has arrived in Seville. Good afternoon, ladies and gentlemen, and welcome to follow Orion Corporation's webcast. And now, let us turn to the teleconference, where today we discuss our half-year financial report for 2024, which we published just a couple of hours ago. My name is Tukur, and I'm the head of IR here at Orion. In a few moments, our CEO, Lisa Herman, will go through the key events and main topics of the reported period, after which you will have the opportunity to ask questions either from her or from our CFO, Mr. Rene Lindell. We will first take questions through the conference call lines, after which we will turn to the webcast. And to those who are presenting questions through the teleconference lines, we kindly ask that you state your name and the organization you represent before asking your question. As usual, I'd like to draw your attention to this disclaimer regarding forward-looking statements. And with that, I will conclude and hand over to Lisa.
Thank you, Tuukka, and a very good afternoon to all of you. A very good morning to all, wherever you find yourselves. Welcome to the Orion Corporation half-year webcast. But let's start with Q2. Our Q2 was very strong both in net sales and operating profit. Our net sales grew 13%, or 13.4% to be exact, and our operating profit grew 41.5%. The net sales growth was driven mainly by Nubeqa® royalties and product sales, and also good performance of our Animal Health portfolio. Also, our operating margin increased from 16.1% to 20.1%. And of course, it's great to present such a significant improvement in operating profit. It is exactly according to our financial objectives. As we've stated, we are increasing our R&D investments, and that's what we've done. And we can still show growth in our operating profit. Now let's move to the half-year figures and events. Similar trend here. Net sales increased by 12.2%. Orion Corporation is the leader in Animal Health. Main drivers: operating profit increased by 19.5%. And here's Becca again as the main driver. And similarly with the half-year numbers, despite the higher R&D expenses, we still managed to show very good profitability and an increase. And also in our operating profit, cash flow clearly improved from the previous year, and this is due to the Orion Pension Fund B transfer, and also the new bake sales milestone of 30 million that were actually in our cash only this year, even though they were booked to the previous year, and no royalties and product sales, of course, have a positive impact on cash flow as well. When we look closer at the net sales, it's noticeable here in column two. Uh, €38.1 million during the first half of the year. But when you calculate together all the other products. Easyhaler®, the other portfolio, including generics and also Animal Health in addition to oncology, together are almost or are as high as Nubeqa® alone. Which means that all the divisions are contributing to Orion's growth. On the negative side. The usual suspects, Dexmedetomidine and same drugs, uh, prices are declining and, uh, somewhat also volumes and also intercompany sales are declining due to price erosion. Volumes are still growing. Regarding the operating profit, we observe positive product sales, without the need for sales matching or product mix adjustments, as shown in the first column here, amounting to 32.6 million. And then the effect of the product mix and the matching. This column, for instance, includes both Dax and Dexter intercompany price erosion and then royalties of 29.2 million. And the last column here, marked as fixed cost, tells the story of increased R&D investment. Of course, this $24.2 million also includes other costs and R&D expenses. Another significant expense is the IMM costs and our ERP program which we are currently implementing. Now, I moved the divisions and I started with innovative medicines, showing very healthy growth driven by Nubeqa® and Animal Health, where sales were 121.1 million. We discussed various types of products and, of course, also introduced new developments. We are continuing to undergo pricing and reimbursement negotiations for Stormy in major European countries. Brandy products here also showed a very nice growth figure of 11.3% and were easily the biggest product driving the growth. Demand is very strong in the market, partly due to the green wave that we can address, but also partly due to the general increase. Although the increase is slow, it is still an increase in the market. Inter-company activity, as I already mentioned, is decreasing to some degree, but there is very nice growth in women's health. Although it's a small business, we have other products in the branded division as well. There are some smaller CNS products and also some products for asthma and COPD. And those are also growing. This supports our strategy, and I hope we'll see larger figures as we progress through the coming years, as we are focusing on building our Parkinson's disease product portfolio with intercompany products. And on that note, we have signed a license agreement with Narva Medic and a Norwegian company on disposable, water-soluble micro tablets of levodopa and carbidopa, for the treatment of Parkinson's disease. Later stages. So this is just an example of one product that serves as an example of increasing the number of Parkinson's disease drugs in our portfolio. Now, generics and consumer health are almost on par with last year at -1.2%. Of course, here, as I often say, if you exclude Dexmedetomidine and Simdax, especially in Russia, last year we sold remaining inventories in Russia. So that, of course, creates some difference in comparison to this half-year of generics and consumer health. Our basic generic portfolio is experiencing and showing very healthy growth with single-digit percentages. And here we can see that Finland is the single biggest market for our generic and consumer health products. Animal Health has shown very nice growth. External sales are growing. Although 'fermion' is 'fermions', capacity is very much tied to the manufacturing of increasing volumes of data. Glutamate for new become. Here is our top ten list. Here we have the new data with 46.9% growth. The Taylor product portfolio exhibited a 19% growth compared to the previous year's first half. A couple of products experienced slight declines due to price erosion in different countries around the globe. And here I also want to underline that the use of stable and consistent content is actually increasing by volume. Our sedative portfolio grew 46.7%, also showing a solid 17% growth, while bananas were more or less on par with the previous year. Same text we already discussed. The last two products are mainly partner sales, so they may change quite a lot between different quarters and between different years, depending on the deliveries to our partners. We have had a busy summer with some news. Uh, and I'll go through those now in my next section of this presentation. We have reported that we and MSD have exercised the option regarding the opevesostat treatment for prostate cancer, so that the codevelopment and commercialization agreement with MSD was converted into a license agreement, which means that Merck now has global rights for opevesostat. This license agreement provides Orion with a substantial milestone package of €1.1 billion. The package is divided into three segments. There are development, milestone payments, approval and regulatory milestone payments, as well as sales milestone payments. Of course, in a similar way as with Nubeqa® to reach the highest level. I mean, in this case, the low 20s of royalties the product would need to reach several billion. Of market sales. Orion continues to supply the product to Merck as earlier, and in the context of converting this co-development and commercialization agreement to an exclusive license agreement with Merck. We also released a 60 million item from our balance sheet, and this will create a positive impact on our third-quarter operating profit. And due to this, we upgraded our outlook for the year 2024. So, this ongoing year until the 1st of July factors into that outlook. Of course, there were some other reasons, and I'll get back to that at the end of the presentation when we discuss the outlook. The second event after the end of the second quarter was the reporting of the phase three study named Renewed, which analyzed our new backup. The study met the primary endpoint of radiological progression-free survival, which was the primary goal. We compared this new backup, combined with androgen deprivation therapy, to placebo and androgen deprivation therapy alone. This phase three study also reconfirmed, the safety and tolerability of the new treatment. We've observed the same safety and tolerability profile in the earlier studies of ARAMIS among others. Bayer plans to present this pivotal data at upcoming scientific congresses. Additionally, preparations are underway to submit the data to health authorities globally. An expansion to the current indications based on these results is also planned. Otherwise, our pipeline remains consistent. Regarding ODM 111, we have completed phase one studies and are preparing to initiate the phase two program, including studies on acute and two types of chronic pain. This program is global and covers several indications, with plans to start by the end of 2024 or early 2025. Now, to a very different subject. This involves sustainability and encompasses 6000 suppliers in 60 different countries, dealing with various needs such as drugs, medicines, APIs, raw materials, and different components of our manufacturing processes. Obviously, managing such a vast network of suppliers needs careful attention. We have been working consistently, over decades, to develop an extremely robust, visible, and transparent process for managing our suppliers. This approach is integral to our sustainability efforts. We demand adherence to the code of conduct from our suppliers. We have incorporated scope three carbon emissions into these collaborations. Most importantly, it requires a strong collaboration with your suppliers. Many of our suppliers have been our partners for a long time and play a critical role, particularly for a mid-sized European company operating in sectors like generics, innovative medicines, and branded products. Most notably, we have been recognized, as demonstrated in this slide, by many experts in the sustainability field that our work in managing supply chains is at an excellent level. Moving onto the outlook for this year. This was updated on the 1st of July. As previously mentioned, the update was mainly due to the 60 million items that were released from the balance sheet. But that was not the only reason. Also, the beginning of the year has been better than we anticipated or estimated at the onset. That's clearly another reason for this update. And of course, reporting these half-year results. This also shows. So now, our target, or the outlook for 2024, is between 1,040 million euros to 1,480 million euros. And then the operating profit is projected to be €350 to €380 million. You can see the upcoming events listed here. We will report next on the 29th of October. And then we report the third quarter and the first nine months of this year. And the final financial statement of the ongoing year will be on the 25th of February. I thank you for your attendance.
Thank you, Lisa, for the presentation, and it's my pleasure to also invite Renee to the podium as we'll turn to the Q&A session. As mentioned, we will start with the conference call line. So at this stage, I will hand over to the teleconference. Operator, please.
If you wish to ask a question, please dial the pound key followed by five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key followed by six on your telephone keypad. The next question comes from Victor Sundberg at Nordica. Please go ahead.
Hi.
Mr. Sandberg is on the app. And thanks for taking my questions. I have two questions, if I may. First, regarding the royalty revenue dynamics, it appears that darolutamide has really accelerated this factor in the US and globally. So, I'm just wondering, from a modeling perspective, how does this impact your product sales versus what I would call the pure royalty rate that you're getting from Bayer? Have you already supplied ahead of this increased uptake of the sector, or should we expect increased product sales initially? If demand gets more pronounced here, from the anesthesia setting or just in general? Thanks.
Well, let me start and then continue. Clearly, Nubeqa® is accelerating on its growth curve and trajectory. Uh, I think the line was a bit bad. I think you mentioned anesthesia as well, but we are not expecting anesthesia to contribute to this trajectory. At least this year. You know, Bayer is only now going to file the application for the indication expansion. But you also mentioned product sales that may be renewed or you picked up the rest of the question.
Indeed, it might be referring to that the sales base for Nubeqa® is growing well. And of course, we expect that we will get additional requests for tablet deliveries. So those should also increase with the total sales. But those come a bit unpredictably. So it really depends on how we receive the orders and from Bayer. And then we provide those. So there will be some fluctuation for sure.
There is always fluctuation. And I think we've discussed this before. But when you look at the slides, you can clearly see that, uh, this quarter, quarter two was the second almost all-time high for product deliveries from Nordica to Bayer, which, of course, indicates the growing trajectory of the product.
Thank you. And the second question, just on OTM 111, where are you in that preparation and how can that potentially impact your guidance? I mean, are the costs to start the study material in your opinion, so that it turned out that you start the study on the other side of the year. Could that mean that you end up above your guidance, for example, due to costs not taking place this year? And also, if I can squeeze in maybe just a comment also on your expectation on the pricing environment for this kind of product which has the FDA approval, a vertex drug at the end of January next year. Thank you.
The question was regarding OTM 111 and preparations for the phase two program. Of course, preparing for such a big global program with several indications takes time. And you have your negotiations with all the different types of medical, um, regulatory authorities and, as soon as all the preparations are ready and all the consultations are done, we will be able to start hopefully by the end of this year. But since these are lengthy processes and complicated, it may also be in the beginning of 2025. If I understood or heard correctly. You also were discussing whether this has an effect on our numbers, whether it happens in 2024 or 2025. I don't think it's a big effect on those numbers, as all the preparations are still ongoing. Of course, the biggest lump sum sale is always paying for the trials to start the studies. But it's difficult to estimate right now where those payments will be timed. You know this towards the end of the year. I think the question was regarding pricing of this type of product, but it is a very good question. Maybe it's a bit too early to ask that now. I think we need to proceed with our studies to see the efficacy of the molecule and the safety of the molecule. Of course, there is another company ahead of us and I think we, as well as everybody else following this segment, will see then how this type of product will be priced and reimbursed.
Thank you very much. That's all for me. Thanks.
The next question comes from Anthony Rousey from CB. Please go ahead.
Thank you. And hi to all. Thank you, Lisa and Greg, for the presentation. If I may continue on Victor's questions a bit about Becca and your guidance. Mike, did you see that Rebecca is already selling? Maybe better than expected, due to your higher product deliveries? Or how do you see the situation since you upgraded your guidance in early July?
Yeah, maybe I can take this one. So of course, it's the totality of the business. And we have to look at the actual figures that we had in H1. And those were, you know, the basis of that, and of course, always making the best possible prediction of where this year is heading. But there is a lot of uncertainty. You can see that in the range as well when we provide our outlook. So there is a broad range of scenarios. And of course, the deliveries themselves might indicate, of course, there's a good demand for the product. But it's also about inventory management. So we don't know how much that is being managed on the buyer's side. So those don't necessarily always correlate with actual sales because you might also deliver products to ensure that you have inventory for different scenarios going forward and even next year.
And that.
I think that's clear now about your old M2 or, wait, possible royalty rates. Just to clarify that, was it so that your royalty rate is the net royalty rate and, uh, product deliveries will be booked as, you know, zero margin sales separately?
If not, I can take it.
Yeah.
Thanks for the question. So probably you are asking this question because with Bayer we have this kind of arrangement where the royalty is the only income Orion gets, and we need to then cover the cost of goods sold with that amount. But the agreement with MSD or Merck is a bit different. So as you said, the royalty will be pure royalty. And when we are delivering tablets to Merck they will be invoiced separately. So, it's a different kind of agreement than we have with Bayer.
Exactly. Now, focusing on tax. And maybe finally about the gain. Excellent. So do you have an updated timetable for this as well as for the future? So if Mariano's Pharmaceuticals is successful with other indications, do you have to go through the same process in Europe for every future indication?
Mhm.
Indeed. Unfortunately, I cannot comment. Do you have a more specific timetable for the first indication, where we are now negotiating with the pricing authorities? Let's hope something happens soon. For the second indication. We are expecting phase three results toward the end of the year. And yes, you are right, for all indications we need to go through the same or new pricing and reimbursement negotiations with the health authorities.
Thanks. I know that you haven't commented officially on the connection potential, and you have highlighted that this is a small indication, the first one, but can you give us any update regarding the potential of this first indication yet?
Well, I can only reiterate the word 'small' regarding the patient number. In Europe, these children suffering from this hereditary epilepsy. It's hundreds, just hundreds of patients. So it's not even thousands of patients. Maybe that already tells you that when I say small, it is indeed small. And, because it's such a small population, it is important to have the pricing and reimbursement at the right level.
Okay. Thank you. That's all from me.
The next question comes from Sami Sarcomas from Danske Bank. Please go ahead.
Hi, I have a couple of questions. Starting from two topics that have already been discussed, and then moving on to other topics. Firstly, I think you're not really willing to provide any forward-looking information, but if we look at the number you reported for the second quarter as Bayer sales, was that your estimate or was that based on the actual number reported by Bayer this week? And if it was your estimate, when did you make the estimate?
Yeah.
So basically, we always lag behind Bayer. When we receive the reports and when they report as well. Most of that quarter is based on reports. But, of course, the end of the quarter is still based on an estimate. But one could say, two-thirds is basically based on actual reports. So, that kind of reduces the uncertainty. Of course, there's always a chance for flaws depending on the developments in the next quarter and the subsequent report.
Ok. So, you're receiving monthly sales reports from Bayer, I presume. Mhm.
That's correct.
Okay.
Moving on to opevesostat. I think it seems a bit delayed. Can you discuss why it is taking longer to get it going? And did I understand correctly that you're planning three separate phase two studies: one for acute pain and two for chronic pain?
Indeed, you got it right. There will be three different applications: acute post-surgical pain or post-operative pain, focusing on both the body ectomy and soft tissue surgeries. And then there will be two chronic conditions. This much I can tell you. For osteoarthritis and neuropathic pain. This is taking time because, I believe this is very typical. As these are complicated studies in the pharmaceutical industry, particularly when you conduct global studies, with multiple continents and indications involved. The complexity multiplies with different regulations and discussion requirements. It's prudent to have expected that it may start in early 2025.
Moving on to another topic, you're still expecting flat sales for the full year, even though sales were down 8% in the first half of the year. I think you're working on reacquiring distribution rights in Japan. Does this account for the more positive outlook for the second half of the year? Any insights on the timing for this arrangement?
Oh, yes. That partly explains the positive improvements anticipated towards the year's end. We are transferring the distribution rights back from Novartis in Japan. The licensing agreement is scheduled to conclude by the end of the year. So, there is nothing very exciting there. This is also a routine procedure in the pharmaceutical industry. When you license out your products to another company, and then when the time comes and agreements are discussed, both companies decide whether the rights are returned to the originator. Uh, we have already proceeded in Japan, so the labor and inter-company products are not the only ones we are repatriating. We will also repatriate the vehicle in Japan, and in which order these repatriations will occur is, of course, difficult to say, but we definitely hope that all the repatriations will happen by the end of this year. And regarding Orion Corporation's operations in regions like Antigua and Japan, which are significant single markets, will have a positive effect on ending this year. However, even though it has been sliding down now, on the first half of the year, it's due to price erosion. But we strongly believe that, working actively again in Europe, in the selected countries, will increase our volume so that we will get back. Back on the same level as last year.
Okay, then moving on to inhalers, where growth slowed down to single-digit levels in the second quarter. I understand that you are comparing the entire figures from last year, but is this high single-digit growth rate a good assumption for your growth going forward?
Well.
It's difficult always to assume how the full year will go, but I think it will be around low single digit numbers. As we look at the first half-year numbers, there was 19% growth. So I think it's very healthy growth for a brand. Let's remember this is a brand that is 30 years old. So, it has really experienced a revival, you know, for several reasons. And, of course, we have more resources behind the brand now.
Okay, and then my final question would be on Animal Health, where, you know, we had inventory issues last year. Just want to make sure that, uh, you know, we are not getting surprised by those, uh, in the other direction. We have seen quite healthy growth during the first half of the year. Is this a sustainable recovery rate, or could we see that inventories are starting to get filled on this product?
Well, I surely hope that's not the case. We see that this is back. We are getting back to normal after COVID, and after the destocking, so I surely hope we are not going to see anything like that again.
Okay.
The next question comes from Iris Tiedemann from Carnegie. Good morning and thank you for joining us today for the presentation of Orion Corporation's half-year financial report, covering the period from January to June 2024.
Hi all, and thank you for taking my questions. I think I have two questions left. So, first of all, considering your age, do you anticipate more challenges in the second half of the year compared to the first half, in terms of costs, sales, or any factors related to goods that could potentially exert more pressure on your underlying results than in the first half?
Yeah, I think.
Then, okay. Yeah. Go ahead.
Yes, regarding whether we see any headwinds, particularly on the cost side, for H2. So, I believe there's nothing major. I mean, we have already mentioned that R&D expenses will grow somewhat because of OTM 111 and other projects, but these are all included within our outlook as well. So, there are some scenarios depending mostly on R&D that can change where you fit in that outlook area. But otherwise, no headwinds exist.
No, I wouldn't say so. Of course, you can never anticipate global events. But as we see it now,
Nothing concerning is apparent at this point in time.
Okay. And, yeah. Secondly, concerning Japan, How many salespeople will you have, and how much will this increase your costs? And then, considering your long-term outlook in Japan, do you believe you have the potential to grow sales?
Well, I am not prepared to disclose any exact numbers concerning our sales force or our organization in Japan. We will have all the necessary personnel for this diverse portfolio. And regarding the Parkinson's disease products, We are familiar with these from our experience in Europe and have long-term plans. Absolutely, we have strategies for the long term in Japan. We wouldn't consider entering the market otherwise. Investing in a new geographical market is indeed a significant commitment. As Japan is the third-largest pharmaceutical market globally, It is crucial for us to generate growth within. I should mention that we are introducing products related to Parkinson’s disease and women’s health to Japan. We can reintroduce the products. Looking long term, it’s pertinent that we have ordered OTM 111 and are developing other new entities for our pipeline. This lays the foundation for future clinical trials. We intend to conduct these trials independently and, hopefully, one day launch our products in Japan.
Okay.
Thank you.
There are no more questions at this time. So, I hand the conference back to the speakers for any closing comments.
All right. Thank you for participating in the conference call. We have a couple of questions here in the webcast. The first one is related to you, Pekka, maybe already repeated, but I guess that, you know, it's good to repeat so that the market understands the dynamics. So, the question comes from, well, his question is Bayer reported 78% growth in the first half of this year and around 46%. So, does this mean additional revenues will be recognized in Q3? Meaning that it is transferred from H1.
Yes, I can answer that. You can't directly draw a conclusion from Bayer's growth figures into our net sales. And that's due to a couple of factors. One is the timing. And then the second big factor is the tablet sales which basically are deducted from the royalties. Depending on how those come in and also how the inventory build-up is managed to meet future demand as well, it means that these are not directly linked and cannot be compared as such. Of course, there's some correlation. So, if we look at our Q1, Q2, just the royalties growth, then we saw that in Q2 the royalties grew faster than in Q1. So there is some correlation, but it's not mathematically exact.
Yes, and of course, the royalties are increasingly growing towards the end of the year because the royalty rate increases throughout the year. So, there are many variables impacting that. All right then, another question comes from Andreas Hofstetter regarding Precip Fit. It's about the licensing deal within branded products. Can you indicate what impact the new product will have on your Parkinson's portfolio, and what are your expectations when it comes to market penetration and revenue contribution? A couple of years from now?
Good question. Of course, we've estimated and forecasted how the product will perform, but let me first say a few words about the product itself. It would offer an option for patients before the Parkinson's disease symptoms get so severe that you either can't treat them properly or you move to other treatments, which involve an intestinal dopamine treatment. So, it's a significant patient segment. But, it's not the blockbuster, let's put it this way. So, it's kind of a middle-sized product in our Parkinson's disease portfolio. So, it will not be on the scale of Entacapone. Entacapone was at its peak. But it will be a significant product.
All right. Thanks, Lisa. That was all from the webcast. We can still once more turn to the conference call to see whether there are any follow-ups there.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
All right. Thank you. We don't have any more questions either on the webcast. So we can conclude this. Thank you for participating in this webcast today. And the next time we will be reporting results will be at the end of October 29th. So have a great summer until then.
Thank you. Thank you.



















